John Kane, MD

Assessing Clinical Practice Patterns in Treatment-Resistant Schizophrenia

Goal: To assess physicians’ practice patterns in recognition, management, and knowledge of emerging treatments for treatment-resistant schizophrenia (TRS). Methods: • A 26-question a...

John Maeglin , MBA;

Marcello Morgan , MD, MPH;

John Kane , MD;

03/01/2019

Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials

Background: Patients with tardive dyskinesia (TD) often take multiple concomitant medications for psychiatric comorbidities. Data from long-term valbenazine trials were analyzed to evalua...

Richard Josiassen , PhD;

Leslie Lundt , MD;

Andrew J. Cutler , MD;

Khodayar Farahmand , PharmD;

John Kane , MD;

Joshua Burke , MS;

Scott Siegert , PharmD;

03/01/2019

Implementation of Digital Health Technologies for Real-time Monitoring of Patients With Serious Mental Illness: What Lessons Can Be Learned and Applied From Other Specialties?

Introduction: Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver self-reported disease symptoms. New technologies (e.g., mobile-based interven...

Felicia Forma , BSc;

Caroline Huber , MPH;

Wade Aubry , MD;

Darius Lakdawalla , PhD;

John Kane , MD;

Jason Shafrin , PhD;

Meaghan Roach , MPH;

Suepattra G. May , MPH, PhD;

11/22/2019

The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutama...

Andrew Satlin , MD;

Kimberly Vanover , PhD;

Sharon Mates , PhD;

John Kane , MD;

John Edwards , MD, MBA;

Suresh Durgam , MD;

Robert Davis , PhD;

11/22/2019

Neurobiology of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...

John Kane , MD;

Steven Potkin , MD;

Jean-Pierre Lindenmayer , MD;

Ofer Agid , MD;

Christoph U. Correll , MD;

Stephen Marder , MD;

Oliver Howes , MD;

03/01/2019